BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lerner A, Klein M. Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. Brain Commun 2019;1:fcz025. [PMID: 32954266 DOI: 10.1093/braincomms/fcz025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Moline M, Asakura S, Beuckman C, Landry I, Setnik B, Ashworth J, Henningfield JE. The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology (Berl) 2023;240:699-711. [PMID: 36749354 DOI: 10.1007/s00213-023-06320-y] [Reference Citation Analysis]
2 Shojaati N, Osgood ND. An Agent-Based Social Impact Theory Model to Study the Impact of In-Person School Closures on Nonmedical Prescription Opioid Use among Youth. Systems 2023;11:72. [DOI: 10.3390/systems11020072] [Reference Citation Analysis]
3 Horowitz MA, Framer A, Hengartner MP, Sørensen A, Taylor D. Estimating Risk of Antidepressant Withdrawal from a Review of Published Data. CNS Drugs 2023;37:143-57. [PMID: 36513909 DOI: 10.1007/s40263-022-00960-y] [Reference Citation Analysis]
4 Spence AL, Shea LA, Kuhlenberg M, Stroup C, James S, Braun LJ. Basic pharmacology of nonopioid substances. Substance Use and Addiction Research 2023. [DOI: 10.1016/b978-0-323-98814-8.00004-4] [Reference Citation Analysis]
5 Yates JR. Introduction to addiction. Determinants of Addiction 2023. [DOI: 10.1016/b978-0-323-90578-7.00014-1] [Reference Citation Analysis]
6 Zabegalov KN, Galstyan DS, Kolesnikova TO, Kositsyn YM, Gubaidullina MA, Maslov GO, Demin KA, Khatsko SL, Kalueff AV. Modeling the drug withdrawal syndrome in zebrafish (<i>Danio rerio</i>). Rev Clin Pharm Drug Ther 2022;20:185-191. [DOI: 10.17816/rcf202185-191] [Reference Citation Analysis]
7 Kleczkowska P, Zaremba M. An Update of Ketamine Illicit Use. Ketamine Revisited - New Insights into NMDA Inhibitors 2022. [DOI: 10.5772/intechopen.100644] [Reference Citation Analysis]
8 Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, Comer SD, Heal DJ, Hendricks PS, Nichols CD, Sapienza F, Vocci FJ, Zia FZ. Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology 2022;218:109220. [PMID: 35987353 DOI: 10.1016/j.neuropharm.2022.109220] [Reference Citation Analysis]
9 Jia S, Guo X, Chen Z, Li S, Liu XA. The roles of the circadian hormone melatonin in drug addiction. Pharmacol Res 2022;183:106371. [PMID: 35907435 DOI: 10.1016/j.phrs.2022.106371] [Reference Citation Analysis]
10 Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD. Clinical management of cannabis withdrawal. Addiction 2022;117:2075-95. [PMID: 34791767 DOI: 10.1111/add.15743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
11 Saito J, Tachibana Y, Wada YS, Kawasaki H, Yakuwa N, Suzuki T, Yamatani A, Sago H, Murashima A. Transfer of Ethyl Loflazepate Into Cord Blood, Breast Milk, and Infant's Serum: A Case Report. J Clin Psychopharmacol 2022;42:416-8. [PMID: 35343929 DOI: 10.1097/JCP.0000000000001551] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Baumgardt J, Weinmann S. Using Crisis Theory in Dealing With Severe Mental Illness–A Step Toward Normalization? Front Sociol 2022;7. [DOI: 10.3389/fsoc.2022.805604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Horowitz MA, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych advances. [DOI: 10.1192/bja.2021.62] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Boesen K, Paludan-Müller AS, Gøtzsche PC, Jørgensen KJ. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2022;2:CD012857. [PMID: 35201607 DOI: 10.1002/14651858.CD012857.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Davies J, Cooper RE, Moncrieff J, Montagu L, Rae T, Parhi M. The costs incurred by the NHS in England due to the unnecessary prescribing of dependency-forming medications. Addict Behav 2022;125:107143. [PMID: 34674906 DOI: 10.1016/j.addbeh.2021.107143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Horowitz MA, Taylor D. How to reduce and stop psychiatric medication. Eur Neuropsychopharmacol 2022;55:4-7. [PMID: 34688998 DOI: 10.1016/j.euroneuro.2021.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
17 Yeoh SY, Roberts E, Scott F, Nicholson TR, David AS, Rogers JP. Catatonic Episodes Related to Substance Use: A Cross-Sectional Study Using Electronic Healthcare Records. J Dual Diagn 2022;18:52-8. [PMID: 35001837 DOI: 10.1080/15504263.2021.2016342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
18 Sørensen A, Juhl Jørgensen K, Munkholm K. Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. Ther Adv Psychopharmacol 2022;12:20451253211067656. [PMID: 35173954 DOI: 10.1177/20451253211067656] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Boesen K, Paludan-müller AS, Ioannidis JP. Considering the methodological limitations and external validity issues of pharmacological drug trials in adult ADHD: An umbrella review (Open Protocol).. [DOI: 10.1101/2021.12.07.21267067] [Reference Citation Analysis]
20 Mathai DS, McCathern AG, Guzick AG, Schneider SC, Weinzimmer SA, Cepeda SL, Garcia-Romeu A, Storch EA. Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. J Child Adolesc Psychopharmacol 2021;31:553-61. [PMID: 34665021 DOI: 10.1089/cap.2021.0078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Kastner-bosek A, Dajic I, Mikus N, Weidenauer A, Willeit M. Addicted to Self-esteem: Understanding the neurochemistry of narcissism by using cocaine as a pharmacological model. Journal of Experimental Psychopathology 2021;12:204380872110443. [DOI: 10.1177/20438087211044362] [Reference Citation Analysis]
22 Fatoba AJ, Okpeku M, Adeleke MA. Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium. Pathogens 2021;10:921. [PMID: 34451385 DOI: 10.3390/pathogens10080921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Hadler NL, Hairston IS, Conroy DA. Insomnia due to drug or substance abuse and dependence. Reference Module in Neuroscience and Biobehavioral Psychology 2021. [DOI: 10.1016/b978-0-12-822963-7.00014-1] [Reference Citation Analysis]
24 Alsheikh MY. Post-Acute Withdrawal Syndrome: The Major Cause of Relapse among Psychoactive Substances Addicted Users. Arch Pharm Pract 2021;12:91-97. [DOI: 10.51847/ioicfujpnm] [Reference Citation Analysis]
25 Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Ther Adv Psychopharmacol 2021;11:2045125321991274. [PMID: 33796265 DOI: 10.1177/2045125321991274] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
26 Wanigasinghe J, Jayawickrama A, Hewawitharana G, Munasinghe J, Weeraratne CT, Ratnayake P, Wijesekara DS, Fernando S, Rupasinghe P. Experience during COVID-19 lockdown and self-managing strategies among caregivers of children with epilepsy: A study from low middle income country. Seizure 2021;84:112-5. [PMID: 33321430 DOI: 10.1016/j.seizure.2020.12.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
27 Cohen D, Recalt A. Withdrawal effects confounding in clinical trials: another sign of a needed paradigm shift in psychopharmacology research. Ther Adv Psychopharmacol 2020;10:2045125320964097. [PMID: 33224467 DOI: 10.1177/2045125320964097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
28 Claus BB, Specka M, McAnally H, Scherbaum N, Schifano F, Bonnet U. Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor? Front Psychiatry 2020;11:598150. [PMID: 33343424 DOI: 10.3389/fpsyt.2020.598150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Hengartner MP, Schulthess L, Sorensen A, Framer A. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Ther Adv Psychopharmacol 2020;10:2045125320980573. [PMID: 33489088 DOI: 10.1177/2045125320980573] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]